A large body of evidence demonstrated the increased tissue and serum expression of PTX3 in prostate cancer patients, compared to prostatic inflammation and benign prostatic hyperplasia (BPH), thereby encouraging PTX3 evaluation in clinical setting as a central biomarker able to discriminate between the different features of prostate diseases and to predict cancer development [66,67]. The gene discussed is PTX3; the disease is prostate carcinoma.